Abstract
Introduction and hypothesis
To determine if Onabotulinumtoxin A (Botox®) should be offered as a first-line therapy for the treatment of overactive bladder (OAB), even before prescribing anticholinergics.
Methods
We performed a cost-effectiveness analysis modeling the following clinical options: no treatment, non-selective anticholinergics, selective anticholinergics, and Botox®. The model timeframe was 2 years to allow Botox® reinjection and discontinuation of anticholinergics. Multiple efficacy levels included response improvement by < 50%, 50%, 75%, and 100%. Botox® reinjection was allowed at 6 months if < 50% efficacy. Botox® complications and anticholinergic side effects were noted. We modeled up to one medication switch. No crossover from Botox® to anticholinergics or vice versa was allowed, and failures remained with refractory untreated overactive bladder. Medical literature data were used for model parameter values. Costs are 2016 $US.
Results
Botox® costs more than non-selective anticholinergics and less than selective anticholinergics in models with and without refractory overactive bladder costs. Botox® had the highest effectiveness (1.763 quality-adjusted life years). Using incremental cost-effectiveness ratios, Botox® was found to be cost-effective in models with and without refractory costs ($12,428.75 and $14,437.01, respectively). In both models, Botox® cost less and was more effective than selective anticholinergics, which were “dominated.” Over 2 years, subjects averaged 15.6 and 14.3 months on selective and non-selective anticholinergics, respectively, and patients averaged 2.2 Botox® injections. Model results were unchanged with variation of input parameter estimates in sensitivity analyses.
Conclusions
Botox® is a cost-effective therapy for overactive bladder and should be further explored as a first-line option in the treatment paradigm.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Melville JL, Delaney K, Newton K, Katon W. Incontinence severity and major depression in incontinent women. Obstet Gynecol. 2005;106(3):585–92.
Melville JL, Newton K, Fan MY, Katon W. Health care discussions and treatment for urinary incontinence in US women. Am J Obstet Gynecol. 2006;194(3):729–37.
Kinchen KS, Burgio K, Diokno AC, Fultz NH, Bump R, Obenchain R. Factors associated with women's decisions to seek treatment for urinary incontinence. J Women's Health (Larchmt). 2003;12(7):687–98.
Koch LH. Help-seeking behaviors of women with urinary incontinence: an integrative literature review. J Midwifery Womens Health. 2006;51(6):e39–44.
Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004;63(3):461–5.
Burgio KL, Kraus SR, Menefee S, Borello-France D, Corton M, Johnson HW, et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med. 2008;149(3):161–9.
Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;1:CD005429.
Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803–13.
Gormley EA, Lightner DJ, Faraday M, Vasavada SP, Association AU. Society of Urodynamics FmPM. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80.
Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316(13):1366–74.
Visco AG, Zyczynski H, Brubaker L, Nygaard I, Xu X, Lukacz ES, et al. Cost-effectiveness analysis of anticholinergics versus Botox for urgency urinary incontinence: results from the anticholinergic versus Botox comparison randomized trial. Female Pelvic Med Reconstr Surg. 2016;22(5):311–6.
Shepherd JP, Lowder JL, Leng WW, Smith KJ. InterStim sacral neuromodulation and Botox botulinum-a toxin Intradetrusor injections for refractory urge urinary incontinence: a decision analysis comparing outcomes including efficacy and complications. Female Pelvic Med Reconstr Surg. 2011;17(4):199–203.
WebMD. Prescription Drug Prices. [cited 2016 12/15/16]; Available from: http://www.webmd.com/rx
Services CfMaM. Physician Fee Schedules [cited 2016 12/15/16]; Available from: https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx
Bermingham SL, Hodgkinson S, Wright S, Hayter E, Spinks J, Pellowe C. Intermittent self catheterisation with hydrophilic, gel reservoir, and non-coated catheters: a systematic review and cost effectiveness analysis. BMJ. 2013;346:e8639.
François M, Hanslik T, Dervaux B, Le Strat Y, Souty C, Vaux S, et al. The economic burden of urinary tract infections in women visiting general practices in France: a cross-sectional survey. BMC Health Serv Res. 2016;16(a):365.
Kantartzis KL, Shepherd JP. Cost-effectiveness of test phase implantation strategies for InterStim® sacral neuromodulation. Female Pelvic Med Reconstr Surg. 2013;19(6):322–7.
Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian prescription database. Acta Obstet Gynecol Scand. 2013;92(10):1208–15.
Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health. 2005;8(4):495–505.
Fonseca AM, Meinberg MF, Monteiro MV, Roque M, Haddad JM, Castro RA. The effectiveness of anticholinergic therapy for overactive bladders: systematic review and meta-analysis. Rev Bras Ginecol Obstet. 2016;38(11):564–75.
Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93(3):303–10.
Cardozo L, Lisec M, Millard R, van Vierssen TO, Kuzmin I, Drogendijk TE, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172(5 Pt 1):1919–24.
Thomas TN, Walters MD, for the American Urogynecologic Society (AUGS) Guidelines Committee. AUGS Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder. Female Pelvic Med Reconstr Surg. 2017;23(3):177–8.
Noblett KL, Dmochowski RR, Vasavada SP, Garner AM, Liu S, Pietzsch JB. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome. Neurourol Urodyn. 2017;36(3):727–33.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Rights and permissions
About this article
Cite this article
Shepherd, J.P., Carter-Brooks, C.M. & Chermanksy, C. A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder. Int Urogynecol J 29, 1213–1219 (2018). https://doi.org/10.1007/s00192-018-3653-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00192-018-3653-z